Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
MicroPort NeuroScientificHKSE:02172 -1.37%93 Interest Coverage is 363.25 as of Dec. 2025, which is 983% above its 10-year median of 33.53. GuruFocus rates HKSE:02172 with a GF Score™ of 93/100 and a GF Value™ of HK$13.19 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 465 Medical Devices & Instruments companies, MicroPort NeuroScientific ranks better than 84.3% on this metric.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's
Operating Income
by its Interest Expense. MicroPort NeuroScientific's
Operating Income
for the
six
months ended in Dec. 2025 was HK$178.0 Mil. MicroPort NeuroScientific's Interest Expense for the
six
months ended in Dec. 2025 was HK$-0.5 Mil.
MicroPort NeuroScientific's interest coverage for the quarter that ended in Dec. 2025 was 363.25.
The higher the ratio, the stronger the company's financial strength is.
Good Sign:
Ben Graham prefers companies' interest coverage to be at least 5. MicroPort NeuroScientific Corp has enough cash to cover all of its debt. Its financial situation is stable.
The historical rank and industry rank for MicroPort NeuroScientific's Interest Coverage or its related term are showing as below:
HKSE:02172'
s Interest Coverage Range Over the Past 10 Years
Min: 1.34 Med: 33.53 Max: 260.07
Current: 260.07
HKSE:02172's Interest Coverage is ranked better than 84.3% of 465
companies
in the Medical Devices & Instruments industry
Industry Median: 16.85
vs HKSE:02172: 260.07
Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.
Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .
MicroPort NeuroScientific Interest Coverage Related Terms
MicroPort NeuroScientific Interest Coverage Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
HKSE:02172 vs ABT, SYK, MDT: Interest Coverage Comparison
For the Medical Devices subindustry, MicroPort NeuroScientific's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
MicroPort NeuroScientific Interest Coverage vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, MicroPort NeuroScientific's Interest Coverage distribution charts can be found below:
* The bar in red indicates where MicroPort NeuroScientific's Interest Coverage falls into.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MicroPort NeuroScientific (HKSE:02172) has a Interest Coverage of 363.25 as of Dec. 2025. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on MicroPort NeuroScientific and its competitors. This is 983% above median its historical median of 33.53. Over the past decade, MicroPort NeuroScientific's Interest Coverage has ranged from 1.34 to 260.07. According to the industry distribution chart, MicroPort NeuroScientific ranks #73 out of 465 companies in the Medical Devices & Instruments industry, placing it in the top 15.7%.
Is MicroPort NeuroScientific's Interest Coverage too high?
MicroPort NeuroScientific's current Interest Coverage of 363.25 is 983% above median its 10-year median of 33.53. Over the past 10 years, this metric has ranged from a low of 1.34 to a high of 260.07. The Medical Devices & Instruments industry median Interest Coverage is 16.85. MicroPort NeuroScientific's value of 363.25 is 2055.8% above this industry median. Based on the distribution chart, MicroPort NeuroScientific ranks #73 out of 465 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, MicroPort NeuroScientific has a GF Score™ of 93/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does MicroPort NeuroScientific's Interest Coverage compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, MicroPort NeuroScientific ranks #73 out of 465 companies for Interest Coverage. This places MicroPort NeuroScientific in the top 16% of its industry — outperforming the majority of peers. The industry median Interest Coverage is 16.85. MicroPort NeuroScientific's value of 363.25 is 2055.8% above this benchmark. Historically, MicroPort NeuroScientific's own Interest Coverage has ranged from 1.34 to 260.07 over the past decade. While the company's 10-year median is 33.53 vs. the industry median of 16.85, MicroPort NeuroScientific has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Coverage for a Medical Devices & Instruments company?
The median Interest Coverage among Medical Devices & Instruments companies is 16.85, based on 465 companies in the industry. Companies in the top quartile (top 25%) have a Interest Coverage significantly above this median, while those in the bottom quartile fall well below. However, Interest Coverage should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. MicroPort NeuroScientific's current Interest Coverage of 363.25 is 2055.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Coverage mean?
A high Interest Coverage can signal that a stock is expensive relative to its fundamentals. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on MicroPort NeuroScientific and its competitors. For the Medical Devices & Instruments industry, the median Interest Coverage is 16.85 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. MicroPort NeuroScientific's current Interest Coverage is 363.25, which is 983% above median its own 10-year median of 33.53. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MicroPort NeuroScientific stock overvalued right now?
Based on GuruFocus' analysis, MicroPort NeuroScientific (HKSE:02172) is currently considered Possible Value Trap. The stock's GF Value™ is HK$13.19, compared to a current price of HK$9.01 — trading 31.7% below its estimated fair value. The current Interest Coverage is 363.25, which is 983% above median its 10-year median of 33.53 and 2055.8% above the Medical Devices & Instruments industry median of 16.85. MicroPort NeuroScientific's overall GF Score™ is 93/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Coverage calculated?
Interest Coverage is calculated from a company's financial statements. For MicroPort NeuroScientific (HKSE:02172), the current Interest Coverage is 363.25 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is MicroPort NeuroScientific (HKSE:02172) Overvalued in 2026?
Based on GuruFocus' analysis, MicroPort NeuroScientific stock appears to be undervalued.
The current stock price of HK$9.01 is trading 31.7% below its estimated GF Value™ of HK$13.19.
GuruFocus considers MicroPort NeuroScientific to be Possible Value Trap.
Key valuation signals for HKSE:02172:
Interest Coverage: 363.25 (983% above median its 10-year median of 33.53)
GF Value™: HK$13.19 vs. price of HK$9.01 (31.7% below fair value)
Industry Position: 2055.8% above the Medical Devices & Instruments median (#73 of 465)
No single metric tells the full story. See the HKSE:02172 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
MicroPort NeuroScientific Corp is in the neuro-interventional medical device industry, dedicated to providing solutions for physicians and patients. The company boasts a comprehensive portfolio of approved therapeutic products covering all of three main areas of neurovascular disease, namely hemorrhagic stroke, cerebral atherosclerotic stenosis, and acute ischemic stroke. The company generates almost all of its revenue from the sale of medical devices. Geographically, the company generates the majority of its revenue from the PRC region, and also has operations in Israel.
93GF Score
Get the complete analysis for HKSE:02172
Interest Coverage is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:02172 has been successfully added to your 
